Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445330 | 1.00 | ACACB (0.47) | ACACBHRH3CYP2A6GAASMN1; SMN2 | |
| SCHEMBL25801725 | 1.00 | ACACB (0.47) | ACACBHRH3CYP2A6GAASMN1; SMN2 | |
| SCHEMBL16437755 | 0.95 | MMP2 (0.48) | ACACBHRH3CYP2A6ALDH1A1MAPT | |
| SCHEMBL9435217 | 0.95 | MMP2 (0.48) | ACACBHRH3CYP2A6ALDH1A1MAPT | |
| SCHEMBL26383732 | 0.95 | MMP2 (0.48) | ACACBHRH3CYP2A6ALDH1A1MAPT | |
| SCHEMBL9871755 | 0.86 | GAA (0.43) | HRH3CYP2A6GAASMN1; SMN2MAOB | |
| SCHEMBL11527151 | 0.86 | GRIA1 (0.49) | ACACBHRH3 | |
| SCHEMBL11527148 | 0.86 | GRIA1 (0.49) | ACACBHRH3 | |
| SCHEMBL122883 | 0.83 | ACACB (0.45) | ACACBMAPT | |
| SCHEMBL6118370 | 0.83 | LOXL2 (0.44) | HRH3CYP2A6GAASMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | ACACB 358/4885HRH3 545/4885CYP2A6 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.